Medindia

X

Reportlinker Adds Pain Therapeutics 2005: Market Dynamics and Outlook

Wednesday, November 11, 2009 General News J E 4
Advertisement
NEW YORK, Nov. 10 Reportlinker.com announces that a new market research report is available in its catalogue.

Pain Therapeutics 2005: Market Dynamics and Outlook

http://www.reportlinker.com/p0158361/Pain-Therapeutics-2005-Market-Dynamics-and-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

Pain Therapeutics 2005: Market Dynamics and Outlook provides detailed analysis and information concerning the global market for pain therapeutics, R&D pipelines and company involvement in this field.

About one and a half billion people suffer from moderate to severe chronic pain worldwide and approximately 50 million Americans suffer with pain. The value of the pharmaceutical market for pain relief reflects this seeming worldwide epidemic of pain, with the overall value reaching nearly $23 billion in 2004.

In this new report, key pain management therapeutics such as Cox-II inhibitors, opioids, triptans, anticonvulsants and traditional NSAIDs are discussed in terms of their past, present and future value and the role they are playing in the effective management of pain.

The dynamics of this market have been altered greatly over the past year. The troubles surrounding the multi-billion dollar Cox-II class has created a void in the marketplace. Pain Therapeutics 2005 explains just what the Cox-II crisis means for the future of pain management and what kinds of opportunities their failure may present for other classes of pain management medications.

Pain Therapeutics 2005 also analyzes the markets and provides forecasts for:

This 249-page report also includes the following features:

To order this report:

Pain Therapeutics 2005: Market Dynamics and Outlook

http://www.reportlinker.com/p0158361/Pain-Therapeutics-2005-Market-Dynamics-and-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

More market research reports here!

-- the fast-growing anticonvulsant class -- migraine therapies -- traditional NSAIDs -- and opioids.

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Sigma-Aldrich Enters Distribution Agreement With S...
S
Reportlinker Adds US World Nutraceutical Ingredien...